Friday, 7 December 2018

Veritas VCS-275 Question Answer

An administrator runs the following command on the Master Server to r=teat connectivity to a client:
bptestbpcd –client clientA
The administrator receives the following message:
<16> bptestbpcd main: Function ConnectToBPCD (clientA) failed: 25 cannot connect on socket
Which two reasons may cause the error message? (Select two.)

A. an incorrect entry for the Master Server in the client’s hosts file
B. the NeBackup processes on the client are stopped
C. The Master Server is unknown to the client
D. an incorrect entry for the client in the Master Server’s hosts file
E. vnetd is stopped on the Master Server

Answer: AE

Tuesday, 17 July 2018

Veritas VCS-275 Question Answer

Which status code applies only to disk storage units?

A. 129
B. 86
C. 219
D. 2805

Answer: A

Which NetBackup command is used to report the potential free space of AdvancedDisk storage units?

A. nbdevquery
B. bpstuinfo
C. nbemmcmd
D. bpstinfo

Answer: A

Wednesday, 28 February 2018

Veritas VCS-275 Question Answer

An administrator needs to decrease the total amount of time required to back up a UNIX file server, but requires a full backup every night for recovery purposes. How should the administrator proceed?

A. use compression
B. use Accelerator
C. use change journal
D. use client-side deduplication

Answer: B

An administrator needs to duplicate a backup that completed successfully earlier that same day. How can this be accomplished?

A. locate the original backup from NetBackup Management > Reports > Images on Media, right click and select duplicate
B. locate the policy for the original backup and initiate a manual backup
C. locate the policy for the original backup and enable Multiple Copies on the on the appropriate schedule
D. locate the original backup from NetBackup Management > Catalog, right click and select duplicate

Answer: D

Thursday, 28 December 2017

Is It Time To Buy Veritas Investments Limited (NZE:VIL) Based Off Its PE Ratio?

Veritas Investments Limited (NZSE: VIL) operates with a final P / E of 0.5x, which is lower than the industry average of 20.9x. While this makes VIL appear as a large stock to buy, you can change your mind after explaining the assumptions behind the P / E relationship. In this article, I will break down what the P / E relationship is, how to interpret it and what consider.

Demystifying the P / E relationship

A common ratio used for the relative valuation is the P / E ratio. Compare the price per share of an action with the earnings per share of the share. A more intuitive way to understand the P / E relationship is to think about how much investors pay for each dollar of the company's profits.


Price-Earnings Ratio = Price per share ÷ Earnings per share

P/E Calculation for VIL

Price per share = NZ$0.05

Earnings per share = NZ$0.094

∴ Price-Earnings Ratio = NZ$0.05 ÷ NZ$0.094 = 0.5x

 The P / E ratio is not a metric that you see in isolation and only becomes useful when you compare it with other similar companies. In short, our objective is to compare the P / E ratio of the shares with the average of companies that have similar attributes to VIL, such as the useful life of the company and the products sold. A quick method to create a peer group is to use companies in the same industry, which is what I will do. Since similar companies are expected to have similar P / E ratios, we can reach some conclusions about the stock if the proportions are different.

With 0.5x, the VIL P / E is lower than that of its industry peers (20.9x). This implies that investors are underestimating every dollar of VIL earnings. Therefore, according to this analysis, VIL is a stock at a low price.
Some warnings

However, before rushing to buy VIL, it is important to keep in mind that this conclusion is based on two key assumptions. The first is that our "similar companies" are actually similar to VIL. If the companies are not similar, the difference in P / E could be the result of other factors. For example, if you inadvertently compare lower risk companies with VIL, then the VIL P / E would, of course, be lower than that of its peers, since investors would value those with lower risk at a higher price. The other possibility is if you accidentally compare higher growth companies with VIL. In this case, the VIL P / E would be lower since investors would also reward the higher growth of their peers with a higher price. The second assumption that must be true is that the actions with which we are comparing VIL are justly valued by the market. If this is not fulfilled, there is a possibility that the VIL P / E is lower because the market is overvaluing the companies in our peer group.

What this means for you:

It is possible that you have already carried out a fundamental analysis of the shares as a shareholder, so your current undervaluation could indicate a good purchase opportunity to increase your exposure to VIL. Now that you understand the details of the PE metric, you must know how to take into account its limitations before making an investment decision. Remember that basing your investment decision on a single metric alone is not enough. There are many things that I have not taken into account in this article and the proportion of PE is very one-dimensional. If you have not already done so, I recommend that you complete your research take a look at the following:

    1. Financial health: Are VIL operations financially sustainable? Balances can be difficult to analyze, and that is why we have done it for you. See our financial health controls here.

    2. Previous history: has VIL had a constant performance regardless of the ups and downs of the market? Enter more details in the past performance analysis and take a look at the free visual representations of the VIL records for clarity.

    3. Other high-performance actions: are there other actions that provide better prospects with a proven track record? Explore our free list of these excellent actions here.

Wednesday, 6 September 2017

Veritas VCS-275 Question Answer

The following storage lifecycle policy was used to back up data from a client.
Storage Lifecycle Policy
Backup to AdvancedDisk
Duplication to tape
Duplication to AdvancedDisk
How should an administrator restore data from the tape using NetBackup?

A. From the BAR GUI, select the tape backup to restore from
B. use bpduplicate command to promote copy 1 to the primary copy
C. from the NetBackup Administration console, promote copy 1 to the primary copy
D. from the NetBackup Administration console, promote copy 2 to the primary copy

Answer: A

An administrator tries to suspend an active job from the NetBackup Activity Monitor, but discovers that the option is grayed out. What is preventing the administrator from suspending the job?

A. child jobs are still active
B. the parent job is still active
C. Multiplexing is enabled
D. Checkpoint restart is disabled

Answer: A

Monday, 19 June 2017

Veritas Genetics Welcomes Dr. Robert C. Green and Dr. Natasha Y. Frank to its Medical & Scientific Advisory Board

Veritas Genetics announces Robert C. Green, MD, MPH and Natasha Y. Frank, MD, FACMG, are now members of their distinguished Medical & Scientific Advisory Board. The two respected medical geneticists, known for their extensive experience in genomics, will join an existing team of leading experts who advise Veritas, the leader in sequencing and interpreting the full accessible genome. Both Dr. Green and Dr. Frank are board certified, medical geneticists and medical scientists who serve as medical professors in the Division of Genetics at Brigham and Women's Hospital and Harvard Medical School.

"As genome sequencing begins to play an increasingly important role in adult and pediatric care, it is essential that Veritas has access to the guidance of leading medical professionals," said Veritas co-founder and CEO Mirza Cifric. "Doctors Green and Frank are not only at the forefront of genomics science, they also have a clear idea of how to translate this complex information for patients and make it clinically useful for physicians. As Veritas leads the big shift toward Integrating people's entire genome data into your overall health and lifestyle, we need the advice of our Medical & Scientific Advisory Board to make sure we do it responsibly, efficiently, and with the highest quality standards.

Dr. Green has extensive experience in researching the medical, behavioral, and economic outcomes associated with the implementation of genomic medicine. He leads the Genomes2People Research Program and leads the first randomized trials to explore the implementation of medical sequencing in adults and newborns through the MedSeq and BabySeq projects, which are designed to examine the best way to integrate clinical medicine sequencing with Safety and effectiveness.

"I think sequencing the entire genome will be a natural and necessary part of each individual's health experience from birth," explained Dr. Green. "I am excited to be advising a new company in this space."

Dr. Frank has accumulated extensive experience in the fields of cancer biology, genetics and stem cell biology. He directs research programs funded by the National Institutes of Health, Veterans Administration and the Department of Defense that investigate the biology of stem cells residing in human tissues and their relationship to genetic diseases and cancer.

"We are very fortunate to practice medicine at a time when we can read and understand the human genome," Dr. Frank said. "As a geneticist, I am delighted with the unprecedented opportunities generated by rapid advances in complete genome sequencing technology as well as the opportunity to resolve the most difficult clinical cases and contribute to future therapeutic discoveries."

Physicians Green and Frank will join the following members of Veritas Medical and Scientific Advisory Board:

    George Church, PhD - Co-founder, President of SAB, Veritas. Professor of genetics, Harvard Medical School and MIT. Founding member of the Wyss Institute for Biologically Inspired Engineering, Harvard.
    Peter Blume-Jensen, MD, PhD - Scientific leader in personalized oncology, targeted cancer therapies and biomarkers research. Currently CSO, Xtuit. Former executive, Metamark Genetics, Daiichi Sankyo, Merck and Serono.
    George Siber, MD, PhD - ex EVP and CSO, Wyeth. Faculty at Harvard Medical School and Dana Farber. Currently Associate Professor of Medicine, Johns Hopkins Medical School.
    Scott Patterson, PhD - Formerly Amgen's Executive Director, Medical Sciences, and VP, Proteomics, Celera Genomics. Currently VP, Biomarker Sciences, Gilead Sciences, Inc.
    Scott Parazynski, MD - NASA astronaut and former physiologist with expertise in human adaptation to extreme environments. Professor of Practice, Arizona State University. Product Developer, Stanford MD.
    Shamil Sunyaev, PhD - Professor of Computer Science and Biomedical Medicine, Harvard Medical School. Computational Genomics Chair. Genetic Researcher, Brigham and the Women's Hospital. Associate Member, Broad Institute.
    Hans Lehrach, PhD - Director Emeritus, Max Planck Institute for Molecular Genetics. CEO / CSO Dahlem Genome Research Center and Biology of the Medical System. Founder, Alacris Theranostics Gmbh.

About Veritas Genetics

Veritas is the genome company. We examine most of an individual's DNA through sequencing and interpretation of the entire genome to provide information about the hereditary risks of the disease, the carrier's condition, drug sensitivities, traits and ancestors. Our mission is to help people understand their genetics and make more informed decisions about health and lifestyle with the participation of their physician and access to specialized genetic counselors.

Co-founded in 2014 by George Church and distinguished scientists from the Personal Genome Project of Harvard Medical School, Veritas operates globally from its offices in the United States, Europe and China. The company was recognized by MIT Technology Review as one of the 50 most intelligent companies in 2016.

Wednesday, 3 May 2017

Veritas VCS-275 Question Answer

Which policy directive(s) should an administrator place in the Backup Selections tab to ensure the system is protected when backing up a Windows server?

A. ALL_LOCAL_DRIVES and System State:\
B. ALL_LOCAL_DRIVES and Shadow Copy Components:\
D. ALL_LOCAL_DRIVES and System State:\ and Shadow Copy Components:\

Answer: A

What are two possible causes for job failure when a Windows policy is configured to use Accelerator? (Select two.)

A. client-side deduplication is disabled
B. use of the NTFS Change Journal is disabled
C. the backup target is AdvancedDisk
D. insufficient space in the NetBackup installation directory
E. the policy lacks a forced rescan schedule

Answer: DE